What is the appropriate management of tissue extravasation by antitumor agents?
Review of 175 patients sustaining extravasation of an antitumor agent showed that most (89 percent) can be managed immediately with intermittent application of ice (15 minutes four times daily for 3 days) and close wound observation. We consider pain, usually associated with varying degrees of skin involvement, to be the only indication for surgery. Such a procedure should consist of wide, three-dimensional excision of all involved tissue, temporary coverage with a biologic dressing, and simultaneous harvesting and storage of a split-thickness skin graft. Once the wound is clean, delayed application of the graft is performed (usually at 2 to 3 days). Not only will this result in immediate pain relief and provide safe wound coverage, but it also will not interrupt the patient's chemotherapy schedule. Most patients were able to be restarted on their chemotherapy shortly after surgery, and none demonstrated a "recall phenomenon."
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003630:Daunorubicin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects; D016038:Skin Transplantation; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives; D014750:Vincristine / Q000009:adverse effects; D014751:Vindesine
D000970:Antineoplastic Agents; D008937:Mitomycins; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D014751:Vindesine; D003630:Daunorubicin